NCT06802757View on ClinicalTrials.gov

Posaconazole Plus Pembrolizumab and Chemotherapy vs Pembrolizumab and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

February 1, 2028

Conditions
Breast Cancer
Interventions
DRUG

Posaconazole

Posaconazole 120mg/m2 po bid d1-14 q21d

DRUG

Nab-paclitaxel

Nab-paclitaxel 260mg/m2 d1 q21d

DRUG

Carboplatin

Carboplatin AUC=6 d1 q21d

DRUG

Anthracycline

Epirubicin 90-100mg/m2 d1 q21d or Doxorubicin 50-60mg/m2 d1 q21d

DRUG

Cyclophosphamide

Cyclophosphamide 1000mg/m2 d1 q21d

DRUG

Pembrolizumab

Pembrolizumab 200mg d1 q21d

Trial Locations (1)

250117

RECRUITING

Breast Cancer Center Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan

All Listed Sponsors
lead

Shandong Cancer Hospital and Institute

OTHER